Piper Jaffray analyst William Quirk raised his price target on Idexx Laboratories to $236 and kept his Overweight rating after its Q2 earnings beat and raise of FY18 organic revenue growth outlook. The analyst expects continued favorable conditions in the Companion Animal Group to benefit the stock, raising his target forward earnings price multiple to 46-times from 42-times.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.